These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30218447)

  • 1. Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017.
    Ramamoorthy A; Knepper TC; Merenda C; Mendoza M; McLeod HL; Bull J; Zhang L; Pacanowski M
    Clin Pharmacol Ther; 2018 Nov; 104(5):940-948. PubMed ID: 30218447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
    Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
    Trials; 2016 Apr; 17():199. PubMed ID: 27079511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002.
    Yang Y; Carlin AS; Faustino PJ; Motta MI; Hamad ML; He R; Watanuki Y; Pinnow EE; Khan MA
    J Womens Health (Larchmt); 2009 Mar; 18(3):303-10. PubMed ID: 19243271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial/Ethnic composition of study participants in FDA-approved oncology new molecular entities, 2006-2008.
    Merenda C
    J Natl Med Assoc; 2012; 104(9-10):430-5. PubMed ID: 23342816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender and Ethnicity of Enrolled Participants in U.S. Food and Drug Administration (FDA) Clinical Trials for Approved Ophthalmological New Molecular Entities.
    Birnbaum FA
    J Natl Med Assoc; 2018 Oct; 110(5):473-479. PubMed ID: 30129511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
    Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
    Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.
    Wissing MD; Kluetz PG; Ning YM; Bull J; Merenda C; Murgo AJ; Pazdur R
    Cancer; 2014 Oct; 120(19):3025-32. PubMed ID: 24965506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
    Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
    Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics.
    Varma T; Wallach JD; Miller JE; Schnabel D; Skydel JJ; Zhang AD; Dinan MA; Ross JS; Gross CP
    JAMA Netw Open; 2021 Apr; 4(4):e217063. PubMed ID: 33877309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of worldwide clinical trials by gender: An FDA perspective.
    Ayuso E; Geller RJ; Wang J; Whyte J; Jenkins M
    Contemp Clin Trials; 2019 May; 80():16-21. PubMed ID: 30890465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999.
    Evelyn B; Toigo T; Banks D; Pohl D; Gray K; Robins B; Ernat J
    J Natl Med Assoc; 2001 Dec; 93(12 Suppl):18S-24S. PubMed ID: 11798060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.
    Chen A; Wright H; Itana H; Elahi M; Igun A; Soon G; Pariser AR; Fadiran EO
    J Womens Health (Larchmt); 2018 Apr; 27(4):418-429. PubMed ID: 29048983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.
    Poon R; Khanijow K; Umarjee S; Fadiran E; Yu M; Zhang L; Parekh A
    J Womens Health (Larchmt); 2013 Jul; 22(7):604-16. PubMed ID: 23768021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Representation of women in clinical trials supporting FDA-approval of contemporary cancer therapies.
    Kalathoor S; Ghazi S; Otieno B; Babcook MA; Chen S; Nidhi N; Bae J; Pierre-Charles J; Breathett K; Mazimba S; Johnson A; Brewer L; Mohammed S; Carter RR; Bonsu JM; Ferdousi M; Kola-Kehinde O; McLaughlin E; Brammer J; Ruz P; Khan S; Odei B; Mitchell D; Wei L; Patel P; Paskett ED; Addison D
    Int J Cancer; 2024 Dec; 155(11):1958-1968. PubMed ID: 39155749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs.
    Khan MS; Shahid I; Siddiqi TJ; Khan SU; Warraich HJ; Greene SJ; Butler J; Michos ED
    J Am Heart Assoc; 2020 Jun; 9(11):e015594. PubMed ID: 32427023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
    Leighton JK; Saber H; Reaman G; Pazdur R
    Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessing tumor-related signs and symptoms to support cancer drug approval.
    Williams G; Pazdur R; Temple R
    J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting source.
    Withycombe B; Ovenell M; Meeker A; Ahmed SM; Hartung DM
    J Clin Epidemiol; 2016 Sep; 77():78-83. PubMed ID: 27108488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018.
    Tanaudommongkon I; John Miyagi S; Green DJ; Burnham JM; van den Anker JN; Park K; Wu J; McCune SK; Yao L; Burckart GJ
    Clin Pharmacol Ther; 2020 Nov; 108(5):1018-1025. PubMed ID: 32394430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.